Iron overload and iron chelation in sickle cell disease;Sobrecarga e quelação de ferro na anemia falciforme

Revista Brasileira de Hematologia e Hemoterapia

Volumn 29, Issue 3, 2007, Pages 316-325

  Cançado, Rodolfo Delfini ^a,b  

^a FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

^b Hemocentro da Santa Casa de São Paulo ^*  (Brazil)

Author keywords

Deferasirox; Deferiprone; Deferrioxamine; Iron chelation; Iron overload

Indexed keywords

EID: 38049105797     PISSN: 15168484     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Andrews NC. Disorders of iron metabolism. N Engl J Med. 1999;341:1986-95
2. Porter JB. Practical management of iron overload. Br J Haematol. 2001;115:239-52
3. Piperno A. Classification and diagnosis of iron overload. Haematologica. 1998;83:447-55
4. Andrews NC. A genetic view of iron homeostasis. Semin Hematol. 2002;39:227-34.
5. Camaschella C. Understanding iron homeostasis through genetic analysis of hemochromatosis and related disorders. Blood. 2005;106(12):3710-7.
6. Kushner JP, Porter JB, Olivieri NF. Secondary iron overload. Hematology (Am Soc Hematol Educ Program). 2001;47-61.
7. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994; 331:567-73.
8. Sonakul D, Pacharee P, Thakerngpol K. Pathologic findings in 76 autopsy cases of thalassemia. Birth Defects Orig Artic Ser. 1988;23:157-76
9. Esposito BP, Breuer W, Sirankapracha P, et al. Labile plasma iron in iron overload:Redox activity and susceptibility to chelation. Blood. 2003;102:2670-7.
10. Pootrakul P, Breuer W, Sametband M, et al. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator. Blood. 2004;104:1504-10.
11. Hershko C, Graham G, Bates GW, et al. Non-specific serum iron in thalassaemia: An abnormal serum iron fraction of potential toxicity. Br J Haematol. 1978;40:255-63.
12. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and disease complications in thalassemia major. Ann N Y Acad Sci. 1998;850:227-31
13. Olivieri NF. The beta-thalassemias. N Engl J Med. 1999; 341:99-109.
14. Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med. 2000;343:327-31.
15. Brittenham GM, Badman DG. Non-invasive measurement of iron: report of an NIDDK workshop. Blood. 2003;101:15-19.
16. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonante for the early diagnosis of myocarfdial iron overload. Eur Heart J. 2001;22:2171-9.
17. Fabron A Jr, Tricta F. Terapia quelante oral com deferiprona em pacientes com sobrecarga de ferro. Rev Bras Hematol Hemoter 2003;25(3):177-88.
18. Paula EV, Saad STO, Costa F. Quelação oral de ferro na beta-talassemia. Rev Bras Hematol Hemoter. 2003;25(1):59-63.
19. Ballas SK. Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Semin Hematol. 2001;38(1 Suppl 1):30-36.
20. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89:739-61.
21. Ehlers KH, Giardina PJ, Lesser ML, et al. Prolonged survival in patients with beta-thalassemia major treated with deferoxamine. J Pediatr 1991;118:540-5.
22. Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood. 2006;107:3436-41.
23. Hider RC, Singh S, Porter JB, et al. The development of hydroxypyridin-4-ones as orally active iron chelators. Ann N Y Acad Sci. 1990;612:327-38.
24. Olivieri NF, Brittenham GM, McLaren CE, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med. 1998;339:417-23.
25. Ceci A, Baiardi P, Catapano M, Felisi M, Cianciulli P, De Sanctis V et al. Risk factors for death in patients with beta-thalassemia major: results of a case-control study. Haematologica. 2006; 91(10):1420-1.
26. Maggio A, D'Amico G, Morabito A, et al. Deferiprone versus deferoxamine in patients with thalassemia major: A randomized clinical trial. Blood Cells Mol Dis. 2002;28:196-208.
27. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107:3738-44.
28. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood. 2006;107:3733-7.
29. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol. 1998;103:361-4.
30. Mourad FH, Hoffbrand AV, Sheikh-Taha M, et al. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol. 2003;121(1):187-9.
31. Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood. 2003;102:1583-7.
32. Link G, Konijn AM, Breuer W, Cabantchik ZI, Hershko C. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in ironloaded rat heart cells in culture. J Lab Clin Med. 2001;138:130-8.
33. Grady RW, Giardina PJ. Iron chelation: rationale for combination therapy. In: Dadman DG, Bergeron RJ, Brittenham GM, eds. Iron Chelators: New Development Strategies. Ponte Vedra Beach, FL: Saratoga; 2000:293-310.
34. Galanello R, Piga A, Alberti D, et al. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol 2003; 43:565-72.
35. Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, doubleblind, placebo-controlled, dose-escalation trial. Lancet 2003;361:1597-1602.
36. Piga A, Galanello R, Cappellini MD, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006;91(7):873-8.
37. Glickstein H, El RB, Link G, Breuer W, Konijn AM, Hershko C, et al. Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood. 2006;108(9):3195-203.
38. Wood JC, Tyszka JM, Carson S, Nelson MD, Coates TD. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood. 2004;103:1934-6.
39. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107:3455-62.
40. Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136(3):501-8.
41. Styles LA, Vichinsky E. Effects of a long-term transfusion regimen on sickle cell-related illnesses.J Pediatr. 1994;125(6):909-11.
42. Miller ST, Wright E, Abboud M, Berman B, Files B, Scher CD, et al. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. J Pediatr. 2001;139(6):785-9.
43. Harmatz P, Butensky E, Quirolo K, Williams R, Ferrell L, Moyer T, et al. Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood. 2000;96(1):76-9.
44. Silliman CC, Peterson VM, Mellman DL, Dixon DJ, Hambidge KM, Lane PA. Iron chelation by deferoxamine in sickle cell patients with severe transfusion-induced hemosiderosis: a randomized, double-blind study of the dose-response relationship. J Lab Clin Med. 1993;122(1):48-54.
45. Cohen AR, Martin MB. Iron chelation therapy in sickle cell disease. Semin Hematol. 2001;38(1):69-72.